Postpartum Depression

FDA Panel Votes on Postpartum Depression Treatment Zulresso

By November 06, 2018

If approved, Zulresso would be the first drug approve for the treatment of postpartum depression.

ACOG: Revised Committee Opinion on Postpartum Care Released

By April 25, 2018

Previously, ACOG had recommended a comprehensive postpartum visit occur within the first 6 weeks after birth.

Positive Results for Brexanolone in Postpartum Depression Trials

By November 10, 2017

The Hummingbird Phase 3 program included two Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled trials designed to evaluate the safety and effectiveness of brexanolone in women with moderate and severe PPD.